We are analyzing https://link.springer.com/article/10.1007/s11307-006-0064-1.

Title:
Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic Patients | Molecular Imaging and Biology
Description:
Purpose High blood glucose levels may decrease the sensitivity of 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET). The goal of this study was to assess whether intravenous (i.v.) insulin followed by FDG injection 60 minutes later could decrease the blood glucose level of hyperglycemic patients without altering muscular, liver, or lung FDG uptake. Methods We evaluated 53 diabetic patients with a fasting glycemia higher than 7.0 mmol/l. The control group consisted of 53 nondiabetic patients with a normal fasting glycemia. Sixty minutes before FDG injection, all diabetic patients received up to two intravenous bolus of insulin. Regions of interest were drawn over the lungs, heart, liver, skeletal muscles, and over the most active lung nodule, if present, to calculate a standardized uptake value (SUV) normalized to the lean body weight. Results After one or two boluses of insulin (mean 3.4 units), 39 diabetic patients decreased their blood glucose level from 9.4 ± 1.8 to 6.1 ± 1.3 mmol/l. In 14 patients, two doses of insulin (mean 4.5 ± 2.3 units) were not sufficient, but managed to decrease the blood glucose level from 10.6 ± 2.1 to 9.1 ± 2.1 mmol/l. There was no significant difference for the SUV calculated on the lung, liver, heart, and skeletal muscles. No differences were noted in lung tumor uptake in patients who received insulin compared to the control group. Conclusions With a sufficient waiting period between the insulin and FDG injections, an i.v. bolus of insulin makes it possible to effectively decrease glycemia of diabetic patients without increasing muscular FDG uptake.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, pubmed, google, scholar, insulin, cas, patients, glucose, uptake, fdg, imaging, lung, diabetes, cancer, nucl, med, diabetic, blood, access, privacy, cookies, content, research, fdgpet, sherbrooke, publish, search, injection, decrease, study, level, liver, open, influence, clin, data, information, log, journal, molecular, wholebody, positron, emission, tomography, deoxyffluorodglucose, turcotte, leblanc, carpentier, françois, bénard,

Topics {✒️}

delayed 2-deoxy-2-[f-18]fluoro-d-glucose injection 2-deoxy-2-[f-18]fluoro-d-glucose 2-[f-18]-fluoro-2-deoxy-d-glucose 2-[f-18]fluoro-2-deoxy-d-glucose month download article/chapter françois bénard md type 1 diabetes michel leblanc md body fdg-pet imaging article molecular imaging clinical research center low-dose intravenous insulin positron emission tomography blood glucose levels plasma glucose levels diabetes mellitus influence full article pdf privacy choices/manage cookies related subjects blood glucose level blood glucose concentration fdg-pet imaging lean body weight lean body mass article turcotte diabetes affect [ normal tissue accumulation european economic area fasting glycemia higher experimental malignant tumours received insulin compared conditions privacy policy normal fasting glycemia active lung nodule experimental mammary carcinoma diabetic patients received lung fdg uptake pet/ct accepting optional cookies control group consisted sufficient waiting period check access instant access fdg injection fluorine-18-fluorodeoxyglucose uptake main content log primary lung cancer effectively decrease glycemia journal finder publish author correspondence

Questions {❓}

(2005) Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer?
Gorenberg M, Hallett WA, O’Doherty MJ (2002) Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic Patients
         description:High blood glucose levels may decrease the sensitivity of 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET). The goal of this study was to assess whether intravenous (i.v.) insulin followed by FDG injection 60 minutes later could decrease the blood glucose level of hyperglycemic patients without altering muscular, liver, or lung FDG uptake. We evaluated 53 diabetic patients with a fasting glycemia higher than 7.0 mmol/l. The control group consisted of 53 nondiabetic patients with a normal fasting glycemia. Sixty minutes before FDG injection, all diabetic patients received up to two intravenous bolus of insulin. Regions of interest were drawn over the lungs, heart, liver, skeletal muscles, and over the most active lung nodule, if present, to calculate a standardized uptake value (SUV) normalized to the lean body weight. After one or two boluses of insulin (mean 3.4 units), 39 diabetic patients decreased their blood glucose level from 9.4 ± 1.8 to 6.1 ± 1.3 mmol/l. In 14 patients, two doses of insulin (mean 4.5 ± 2.3 units) were not sufficient, but managed to decrease the blood glucose level from 10.6 ± 2.1 to 9.1 ± 2.1 mmol/l. There was no significant difference for the SUV calculated on the lung, liver, heart, and skeletal muscles. No differences were noted in lung tumor uptake in patients who received insulin compared to the control group. With a sufficient waiting period between the insulin and FDG injections, an i.v. bolus of insulin makes it possible to effectively decrease glycemia of diabetic patients without increasing muscular FDG uptake.
         datePublished:2006-10-12T00:00:00Z
         dateModified:2006-10-12T00:00:00Z
         pageStart:348
         pageEnd:354
         sameAs:https://doi.org/10.1007/s11307-006-0064-1
         keywords:
            FDG
            Glucose
            Insulin
            Diabetes
            Imaging / Radiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig6_HTML.gif
         isPartOf:
            name:Molecular Imaging and Biology
            issn:
               1860-2002
               1536-1632
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Eric Turcotte
               affiliation:
                     name:Centre Hospitalier Universitaire de Sherbrooke
                     address:
                        name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michel Leblanc
               affiliation:
                     name:Centre Hospitalier Universitaire de Sherbrooke
                     address:
                        name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:André Carpentier
               affiliation:
                     name:Centre Hospitalier Universitaire de Sherbrooke
                     address:
                        name:Division of Endocrinology and metabolism, Department of Medicine, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:François Bénard
               affiliation:
                     name:Centre Hospitalier Universitaire de Sherbrooke
                     address:
                        name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic Patients
      description:High blood glucose levels may decrease the sensitivity of 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET). The goal of this study was to assess whether intravenous (i.v.) insulin followed by FDG injection 60 minutes later could decrease the blood glucose level of hyperglycemic patients without altering muscular, liver, or lung FDG uptake. We evaluated 53 diabetic patients with a fasting glycemia higher than 7.0 mmol/l. The control group consisted of 53 nondiabetic patients with a normal fasting glycemia. Sixty minutes before FDG injection, all diabetic patients received up to two intravenous bolus of insulin. Regions of interest were drawn over the lungs, heart, liver, skeletal muscles, and over the most active lung nodule, if present, to calculate a standardized uptake value (SUV) normalized to the lean body weight. After one or two boluses of insulin (mean 3.4 units), 39 diabetic patients decreased their blood glucose level from 9.4 ± 1.8 to 6.1 ± 1.3 mmol/l. In 14 patients, two doses of insulin (mean 4.5 ± 2.3 units) were not sufficient, but managed to decrease the blood glucose level from 10.6 ± 2.1 to 9.1 ± 2.1 mmol/l. There was no significant difference for the SUV calculated on the lung, liver, heart, and skeletal muscles. No differences were noted in lung tumor uptake in patients who received insulin compared to the control group. With a sufficient waiting period between the insulin and FDG injections, an i.v. bolus of insulin makes it possible to effectively decrease glycemia of diabetic patients without increasing muscular FDG uptake.
      datePublished:2006-10-12T00:00:00Z
      dateModified:2006-10-12T00:00:00Z
      pageStart:348
      pageEnd:354
      sameAs:https://doi.org/10.1007/s11307-006-0064-1
      keywords:
         FDG
         Glucose
         Insulin
         Diabetes
         Imaging / Radiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11307-006-0064-1/MediaObjects/11307_2006_64_Fig6_HTML.gif
      isPartOf:
         name:Molecular Imaging and Biology
         issn:
            1860-2002
            1536-1632
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Eric Turcotte
            affiliation:
                  name:Centre Hospitalier Universitaire de Sherbrooke
                  address:
                     name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michel Leblanc
            affiliation:
                  name:Centre Hospitalier Universitaire de Sherbrooke
                  address:
                     name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:André Carpentier
            affiliation:
                  name:Centre Hospitalier Universitaire de Sherbrooke
                  address:
                     name:Division of Endocrinology and metabolism, Department of Medicine, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:François Bénard
            affiliation:
                  name:Centre Hospitalier Universitaire de Sherbrooke
                  address:
                     name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Molecular Imaging and Biology
      issn:
         1860-2002
         1536-1632
      volumeNumber:8
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Centre Hospitalier Universitaire de Sherbrooke
      address:
         name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
         type:PostalAddress
      name:Centre Hospitalier Universitaire de Sherbrooke
      address:
         name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
         type:PostalAddress
      name:Centre Hospitalier Universitaire de Sherbrooke
      address:
         name:Division of Endocrinology and metabolism, Department of Medicine, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
         type:PostalAddress
      name:Centre Hospitalier Universitaire de Sherbrooke
      address:
         name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Eric Turcotte
      affiliation:
            name:Centre Hospitalier Universitaire de Sherbrooke
            address:
               name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
               type:PostalAddress
            type:Organization
      name:Michel Leblanc
      affiliation:
            name:Centre Hospitalier Universitaire de Sherbrooke
            address:
               name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
               type:PostalAddress
            type:Organization
      name:André Carpentier
      affiliation:
            name:Centre Hospitalier Universitaire de Sherbrooke
            address:
               name:Division of Endocrinology and metabolism, Department of Medicine, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
               type:PostalAddress
            type:Organization
      name:François Bénard
      affiliation:
            name:Centre Hospitalier Universitaire de Sherbrooke
            address:
               name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
      name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
      name:Division of Endocrinology and metabolism, Department of Medicine, Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
      name:Sherbrooke Molecular Imaging Center (CIMS), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(72)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.73s.

LINK . SPRINGER . COM {}